The Artificial Intelligence Protein Design Service market encompasses cloud‑based and on‑premise platforms that leverage machine‑learning algorithms, generative models, and high‑throughput simulation to accelerate the design of novel proteins, enzymes, antibodies and therapeutic peptides. This capability is pivotal for shortening R&D cycles, reducing attrition rates, and unlocking biologics that were previously infeasible. The Artificial Intelligence Protein Design Service market size is estimated at $2.1 billion in 2025, and analysts project a robust growth outlook with a CAGR of 27.5% through the market forecast horizon 2026‑2033, propelling the market toward $10 billion by 2033. Primary macro drivers include escalating demand for biologics, exponential growth in computational power, and expanding public‑private partnerships in genomics. Key forces shaping industry expansion are rapid advances in generative AI models, tightening regulatory pathways for AI‑assisted therapeutics, and intensifying competition among biotech firms and cloud‑service giants. North America remains the largest market, while Asia‑Pacific is emerging as the fastest‑growing region.